North America Helicobacter Pylori Non-invasive Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Test Type, Test Method, and End User

The helicobacter pylori (H. pylori) non-invasive testing market in North America is expected to grow from US$ 211.77 million in 2022 to US$ 265.21 million by 2028; it is estimated to grow at a CAGR of 3.8% from 2022 to 2028.

The H. pylori infection is usually developed during infancy but remains asymptomatic, with long-standing clinical symptoms, including gastritis, peptic ulcer disease, and stomach cancer. According to World Health Organization (WHO), in developed countries, the prevalence rate of H. pylori is low, i.e., 50%. Further, the prevalence of gastric disease is significantly higher in the geriatric population as aging increases the risk of H. pylori infection. Over time, aging leads to thinning of the stomach lining, thus allowing the bacteria to pass through the protective lining that contributes to the growing prevalence of infection among older people. According to WHO, the population of people aged 60 years and above is expected to rise. With the subsequent increase in the geriatric population, the demand for primary care services, including screening, assessment, and management of clinical and functional comorbidities, is also growing. These statistics determine the rising need for diagnostics across North America, which is expected to boost the growth of the Helicobacter pylori (H. pylori) non-invasive testing market in the region during the forecast period.

Market Overview

The North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into the US, Canada, and Mexico. North America is the largest market for Helicobacter pylori (H. pylori) non-invasive testing across the globe. The growing prevalence of stomach cancer, duodenal ulcers, and gastric ulcers and the development of healthcare facilities are major growth stimulators for the Helicobacter pylori (H. pylori) non-invasive testing market in North America. The US Department of Health and Human Services report states that ~30-40% of the population in the US suffer from H. pylori infection. Moreover, H. pylori infection is more common in the Hispanic and Black populations in the country due to socioeconomic factors, including low income, less education, household crowding, and immigration into the US. According to the ClinMed International Library report, the first-line drug regimens for the treatment of H. pylori by the Food and Drug Administration (FDA) include proton pump inhibitors (PPI) and two antibiotics or bismuth subsalicylate, acid suppressors, and two antibiotics. With approved first-line drug regimens, there exists resistance to utility. For example, the US eradication rates using these regimens accounted for 75% owing to H. pylori resistance to standard antibiotics. "Clarithromycin" and "Metronidazole" has the highest rate of resistance, and factors associated with resistance involve ethnicity, age, geographic region, and active versus inactive ulcer disease. Hence, The growing prevalence of stomach cancer, duodenal ulcers, and gastric ulcers and the development of healthcare facilities are major growth stimulators for the Helicobacter pylori (H. pylori) non-invasive testing market in the region.

North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Segmentation

The North America helicobacter pylori (H. pylori) non-invasive testing market is segmented on test type, test method, end user, and country. -Based on test type, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market.

• Based on test method, the North America Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022.
• Based on end user, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022.
• Based on country, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into the US, Canada, and Mexico. Further, the US dominated the market in 2022. Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc. are the leading companies operating in the helicobacter pylori (H. pylori) non-invasive testing market in North America.